UK based Stablepharma is delighted to announce that they have been awarded an Innovate UK Smart Grant to advance the development of their disruptive vaccine stabilisation technology, StablevaX™. “This is a very welcome endorsement of our innovative technology to thermally stabilise vaccines”, says Nick Child, Managing Director, Stablepharma Ltd.
This innovative technology will enable vaccines to be thermally stabilised and stockpiled, even in the most inhospitable parts of the world. The StablevaX™ invention aims to negate the expensive and often unreliable ‘Cold Chain’ thereby allowing vaccines to reach everyone, everywhere.
Nick added: “We are delighted to learn that we successfully secured funding of £305,000 from Innovate UK and in addition, the recent news that our patent in the USA has just been granted……is all good news for Stablepharma’’. Further opportunities for use of the technology would be the stabilisation of Covid-19 vaccines, including mRNA in a hope to contribute to the overall challenges of the ‘Cold Chain’ with a co-development partnership opportunities.
Zero refrigeration = eliminate waste = save lives
WHO state that c.50% of vaccines are wasted due mostly to failures in the ‘cold-chain’. This is a clearly identified and unmet need. StablevaX™ has developed a cost effective and simple vaccine delivery system which could align with the global utility of COVID, flu and other seasonal infections. The potential for vertical markets beyond developing-world vaccines, is a strong commercial opportunity.
Barbara Saitta, Medical Advisor of MSF recently told the BBC, ‘Maintaining vaccines under cold chain is already one of the biggest challenges countries face and this will be exacerbated with the introduction of a new vaccine.
Since 2007, Innovate UK has helped over 8,500 organisations create around 70,000 jobs and added an estimated £18 billion of value to the UK economy. During the evaluation of Stablepharma’s application for the grant, an assessor commented that, ‘The applicant has provided a valid and viable approach to addressing the need and challenge which is highly innovative technically, clinically and commercially. The proposed innovation is clearly differentiated from competitor substitute systems.
In the words of Dr Bruce Roser, Chairman & Founder of Stablepharma Ltd, “We have come up with a solution to stabilise vaccines so that they are no longer reliant on refrigeration or ‘the cold chain’ and can be stored at room temperature for long periods of time, even if that is at tropical temperatures. This means that vaccines can be transported around the world without any damage, which ultimately eliminates unnecessary vaccine waste. We are delighted to have received this grant and I am incredibly proud of our team who made this a reality”.